The board of directors of ClouDr Group Limited announced that recently, the Company entered into a service cooperation agreement with JD Health International Inc. to expand online sales and service channels for Remifemin®? and other P2M pipeline products, providing patients with a more convenient medication purchasing experience and professional full-cycle health management services. As the largest pharmaceutical e-commerce platform in China, JD Health boasts a substantial user base and extensive platform resources.
Meanwhile, as a leading chronic disease management platform in China, the Company possesses a unique pipeline of products and expertise in patient- doctor management. The collaboration between the two parties represents a powerful alliance and allows efficient promotion of high-quality, cost-effective medications. To the best of the Board's knowledge, information and belief after having made all reasonable enquiries, JD Health is a third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")).
The Company will comply with the Listing Rules and make further announcement(s) on the potential cooperation as and when appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.
